A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-08-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerbrainbreasttherapyreceiving
  Phrases that lowered it: efficacy andand safetysafety ofparticipantsintended
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 116 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 10.1% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past termination rate: 7.5% (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 186 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 23416 (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban NCT02746185 · started 2016 · scored riskier than 48% of active trials completed
• Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients NCT02583191 · started 2016 · scored riskier than 79% of active trials terminated
• Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines NCT03506815 · started 2019 · scored riskier than 54% of active trials completed
• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) NCT02064439 · started 2014 · scored riskier than 21% of active trials completed
• Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events NCT05515120 · started 2021 · scored riskier than 24% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.